Carboplatin and ifosfamide in ovarian cancer phase II and III trials. London Gynaecological Oncology Group.
Over the past few years controversy has continued as to whether alkylating agents such as cyclophosphamide or chlorambucil are as effective as cisplatin in advanced ovarian cancer. Arguments have also been put forward against the use of combination chemotherapy, which is clearly more toxic than single-agent treatment and is probably no more effective than a single-agent platinum compound except in terms of producing a higher response rate. Certainly survival is not improved.
Royal Marsden Hospital, London, United Kingdom.
E
E
Wiltshaw
T J
TJ
Perren
I D
ID
Fryatt
P R
PR
Blake
P
P
Harper
M
M
Slevin
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010865:Pilot Projects; D011897:Random Allocation; D015996:Survival Rate
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin; D007069:Ifosfamide